Daily Cardiology Research Analysis
Analyzed 204 papers and selected 3 impactful papers.
Summary
A phase 3 randomized trial shows an oral PCSK9 inhibitor (enlicitide) achieves markedly greater LDL-C reductions than other oral nonstatin agents as add-on to statins. A prospective multicenter study identifies a 13 ng/L threshold for a sixth-generation high-sensitivity cTnT assay that safely doubles early MI rule-out at presentation. Global PURE data across 25 countries reveal substantial disparities in heart failure incidence and case fatality, with hypertension as the leading modifiable risk factor.
Research Themes
- Oral lipid-lowering therapeutics and PCSK9 inhibition
- High-sensitivity troponin-based early MI rule-out
- Global epidemiology and disparities in heart failure
Selected Articles
1. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial.
In a double-blind phase 3 trial (n=301), enlicitide reduced LDL-C by 64.6% at day 56 versus −6.3% with bempedoic acid, −27.8% with ezetimibe, and −36.5% with bempedoic acid+ezetimibe; reductions in ApoB and non-HDL-C were similarly superior. Adverse event rates and discontinuations were comparable across arms.
Impact: This is the first head-to-head phase 3 evidence that an oral PCSK9 inhibitor can outperform existing oral nonstatin options as add-on to statins, with substantial LDL-C and ApoB reductions and similar safety.
Clinical Implications: Enlicitide offers a potent oral add-on for very high- and high-risk patients not achieving LDL-C goals, potentially improving adherence versus injectable PCSK9 agents while awaiting cardiovascular outcomes data.
Key Findings
- LDL-C decreased by −64.6% with enlicitide vs −6.3% (bempedoic acid), −27.8% (ezetimibe), and −36.5% (bempedoic acid+ezetimibe) at day 56 (all P<0.001).
- ApoB and non–HDL-C reductions were significantly greater with enlicitide than all comparators (all P<0.001).
- Adverse events and discontinuations due to adverse events were similar across all treatment arms over 56 days.
Methodological Strengths
- Randomized, double-blind, active-comparator phase 3 design
- High background statin use and prespecified lipid endpoints with tight confidence intervals
Limitations
- Short follow-up (56 days) with surrogate lipid endpoints rather than cardiovascular outcomes
- Modest sample size limits rare safety signal detection
Future Directions: Event-driven cardiovascular outcome trials, long-term safety, and adherence/persistence comparisons versus injectable PCSK9 inhibitors.
BACKGROUND: Many adults fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals on statin monotherapy, requiring additional nonstatin lipid-lowering medication. Enlicitide, an oral proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor, lowered LDL-C by 60% compared with placebo; its efficacy compared with other oral nonstatin therapies has yet to be examined. OBJECTIVES: This study assessed the efficacy of enlicitide, a novel oral PCSK9 inhibitor, vs other oral nonstatin therapies. METHODS: In this phase 3, randomized, double-blind, active-comparator trial, statin-treated adults aged ≥18 years with LDL-C ≥55 mg/dL and a previous major atherosclerotic cardiovascular disease (ASCVD) event, or LDL-C ≥70 mg/dL if at intermediate to high risk for a first event, were randomized in 2:1:1:2 fashion to 20 mg enlicitide (n = 101), 180 mg bempedoic acid (n = 50), 10 mg ezetimibe (n = 50), or 180 mg bempedoic acid plus 10 mg ezetimibe (n = 100) once daily for 56 days. The primary endpoint was mean percentage change in LDL-C from baseline to day 56; secondary endpoints included mean percentage changes in apolipoprotein B (ApoB) and non-high-density lipoprotein cholesterol (nonHDL-C). Safety endpoints included overall adverse events (AEs) and discontinuations due to AEs. RESULTS: Among 301 randomized participants (mean age 64.4 years, 37% female, 98% receiving moderate- to high-intensity statin), 298 (99.0%) completed the trial.
2. Early Rule Out of Myocardial Infarction With a Novel High-Sensitivity Cardiac Troponin T Assay.
A 13 ng/L threshold for sixth-generation hs-cTnT at presentation had an NPV of 99.9% and sensitivity of 99.4% for 30-day MI/cardiac death in the derivation cohort (n=987), and NPV 99.0% and sensitivity 97.5% in external validation (n=1721). The new assay more than doubled the proportion ruled out at presentation compared with the fifth-generation assay.
Impact: Defines an actionable presentation threshold for a next-generation hs-cTnT assay with robust external validation, enabling safe single-sample early rule-out and potential ED throughput gains.
Clinical Implications: Adoption of a 13 ng/L presentation threshold could safely increase immediate discharge in low-risk chest pain, reducing serial testing and crowding, pending implementation studies.
Key Findings
- At presentation, hs-cTnT <13 ng/L identified 61% as low risk with NPV 99.9% and sensitivity 99.4% for 30-day MI/cardiac death in derivation.
- External validation identified 45.4% as low risk with NPV 99.0% and sensitivity 97.5%.
- The sixth-generation assay more than doubled early rule-out compared with the fifth-generation assay in both derivation and validation cohorts (P<.001).
Methodological Strengths
- Prospective multicenter derivation with multinational external validation
- Clear performance criteria (NPV ≥99.5%, sensitivity ≥99%) with Bayesian credible intervals
Limitations
- Implementation outcomes (length of stay, safety post-implementation) not tested prospectively
- Assay availability and analytical standardization may vary by site
Future Directions: Cluster-randomized implementation trials assessing safety, resource utilization, and patient-centered outcomes using the 13 ng/L threshold.
IMPORTANCE: In the emergency department, patients at low risk of myocardial infarction can be identified at presentation using a single cardiac troponin measurement with high-sensitivity assay. OBJECTIVES: To define a threshold to identify patients at low risk of myocardial infarction for the sixth-generation high-sensitivity cardiac troponin T (hs-cTnT) assay and to evaluate the impact of applying this in an early rule-out pathway. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective multicenter cohort study conducted from 2022 to 2025 (derivation cohort) and 2014 to 2019 (validation cohort). The setting included emergency departments at hospitals in Scotland (derivation cohort) and Czechia, Italy, Poland, Spain, and Switzerland (validation cohort). Participants included adults with possible non-ST-segment elevation myocardial infarction (both cohorts). Study data were analyzed from May to October 2025. EXPOSURES: Cardiac troponin concentration measured at presentation and on serial samples using fifth-generation and novel sixth-generation hs-cTnT assays.
3. Heart Failure Among 173,000 Community-Dwelling Participants From 25 Low-, Middle-, and High-Income Countries in the PURE Study.
Standardized HF incidence varied widely (highest in sub-Saharan Africa and Europe/Central Asia; lowest in South Asia), while 30-day and 5-year case fatality were markedly higher in LICs (30-day 59%, 5-year 77%) than in HICs (11% and 28%). Over 71% of incident HF was attributable to 13 modifiable risk factors, led by hypertension (PAF 25%).
Impact: Provides robust, globally comparative HF incidence and fatality data with clear attribution to modifiable risks, prioritizing hypertension control and equitable access to care to reduce disparities.
Clinical Implications: Health systems should prioritize hypertension detection/treatment and scale access to guideline-directed HF therapies, particularly in low-resource regions with disproportionate early mortality.
Key Findings
- Overall standardized HF incidence: 0.39 per 1,000 person-years, highest in sub-Saharan Africa (1.18) and Europe/Central Asia (0.86), lowest in South Asia (0.19).
- 30-day case fatality: 59% in LICs vs 11% in HICs; 5-year case fatality: 77% in LICs vs 28% in HICs.
-
71% of HF population-attributable fraction was from 13 modifiable factors; hypertension contributed the largest share (PAF 25%).
Methodological Strengths
- Very large, multinational, community-based cohort with long median follow-up (15 years)
- Standardized incidence and fatality estimates across income strata and regions with PAF analysis
Limitations
- Observational design limits causal inference despite PAF estimates
- Potential heterogeneity in HF diagnosis and treatment access across sites
Future Directions: Implementation research to scale hypertension control and HF therapies in LIC/LMIC settings; harmonized HF diagnostic/management pathways to reduce early fatality.
BACKGROUND: Most population studies examining heart failure (HF) have been conducted in Western high-income countries (HICs), with limited comparable data from lower-income settings. OBJECTIVES: The aims of this study were to describe differences in HF incidence and 30-day, 1-year, and 5-year case fatality rates among HF patients from countries at different income levels and in different global regions and to examine the impact of common and potentially modifiable risk factors for incident HF. METHODS: This analysis of the PURE (Prospective Urban Rural Epidemiology) study included 172,653 individuals from 25 HICs, upper middle-income countries (UMICs), lower middle-income countries (LMICs), and low-income countries (LICs) and 8 geographic regions of the world, followed for a median of 15 years. Age- and sex-standardized HF incidence, as well as 30-day, 1-year, and 5-year HF case fatality, were compared by income group and by geographic region. The population attributable fractions (PAFs) for incident HF related to 13 cardiometabolic, lifestyle, socioeconomic, environmental, and psychosocial risk factors were also estimated.